Megatrends One Year Later – #12: Personalized Medicine – What I Predicted, and What’s Actually Happening

“Tomorrow’s cure lies not in a universal pill, but within our own genetic code.” – Futurist Jim Carroll

One year ago, in July 2025, I published Megatrend #12: Personalized Medicine as part of my 30 Megatrends series. Time to grade myself.

Here’s how I set it up back then:

The one-size-fits-all era in medicine is ending. Treatments, nutrition, and wellness approaches tailored to individual genetic profiles are becoming the standard, not the exception.

We are combining next-generation genomic sequencing, AI, and CRISPR gene editing, to come up with a new health paradigm that involves fixing people before they are sick rather than after.

In February 2026 the FDA introduced a novel regulatory framework specifically for individualized gene-editing therapies. Around the same time, a Philadelphia team developed, got approved, and delivered a personalized CRISPR therapy to a nine-month-old infant with a rare genetic disorder — in six months, start to finish. There are now 4,469 gene and cell therapies in active development — 49% gene therapies, 29% RNA therapies. That’s the “writing the code” pillar, and it’s real.

“Reading the code” moved just as fast. AI variant-interpretation models are now standard in genomic diagnostics, flagging disease-causing mutations and predicting treatment response before a clinician even opens the chart, and 2026 is being called the year AI stopped being optional in drug discovery — target selection increasingly starts with a model, not a wet lab.

The quieter pillar is pharmacogenomics, and it’s the one actually touching ordinary patients: more than 98% of people carry at least one gene variant that affects how they metabolize a common drug, and in 2026 that data is finally inside the prescribing workflow — panel-based PGx testing is routine in oncology, cardiology, psychiatry and pain management, with EHRs flagging gene-drug conflicts in real time. Nutrigenomics and wearable-fed physiological data are stacking on top, tailoring diet and monitoring to that same genetic profile.

Verdict: Nailed it — and it’s bigger than gene editing alone. CRISPR is the headline, but the P4 framework — predictive, personalized, preventive, participatory — is now running quietly in the background of a normal doctor’s visit.